07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

Armetheon, Lee’s Pharmaceutical Holdings Ltd. deal

Armetheon granted Lee’s Pharmaceutical exclusive rights to develop and commercialize tecarfarin in Taiwan, Thailand and China, including Hong Kong and Macau. Armetheon will receive cash and an equity investment up front and is eligible for...
00:51 , Aug 19, 2015 |  BC Extra  |  Company News

Management tracks

Anemia and asthma play Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) named Louis Matis SVP and chief development officer. Matis was executive director of strategic evaluation at Alexion Pharmaceuticals Inc. (NASDAQ:ALXN). Cardiovascular company Armetheon Inc. (Milpitas, Calif.) named...
02:25 , Jun 4, 2015 |  BC Extra  |  Company News

Management tracks

Anti-infectives developer Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) hired Yulii Bogatyrenko as SVP of business development and Randall Brenner as SVP of regulatory affairs and quality. Bogatyrenko was managing partner at Atem Capital, and Brenner was global...
01:37 , Feb 18, 2015 |  BC Extra  |  Company News

Management tracks

Assembly Biosciences Inc. (NASDAQ:ASMB) named President Derek Small as CEO; director William Ringo as chairman; and CFO David Barrett as COO. Small and Ringo succeed Russell Ellison, who was chairman and CEO. Small and Barrett...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Financial News

Armetheon completes venture financing

Armetheon Inc. , Menlo Park, Calif.   Business: Cardiovascular, Infectious   Date completed: 2015-02-05   Type: Venture financing   Raised: $24.3 million   Investors: Hercules Bioventures; Capital TEN II; China Development Industrial Bank; iD SoftCapital...
02:13 , Feb 6, 2015 |  BC Extra  |  Financial News

Armetheon raises $24.3M in series B

Armetheon Inc. (Menlo Park, Calif.) raised $24.3 million in a series B round led by existing investor Hercules Bioventure Partners and new investor Capital TEN II. New investors China Development Industrial Bank Healthcare (CDIB); CDIB...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Financial News

Armetheon completes venture financing

Armetheon Inc. , Menlo Park, Calif.   Business: Cardiovascular, Infectious   Date completed: 2014-08-28   Type: Venture financing   Raised: $7 million   Investors: AshHill Biomedical Investments; Hercules Bioventures; Atheneos Capital; individual investor  ...
07:00 , May 5, 2014 |  BC Week In Review  |  Clinical News

Tecarfarin: SPA received

Armetheon received an SPA from FDA for an open-label Phase III trial to evaluate oral tecarfarin as an anticoagulant in 3,000 patients. The company expects to start the trial in 1Q15. Armetheon Inc. , Menlo...
02:18 , Jan 3, 2013 |  BC Extra  |  Financial News

Heart Metabolics closes series A tranche

Heart Metabolics Ltd. (London, U.K.) raised $4 million in the first tranche of a planned $6 million series A round. Trans Tasman Commercialization Fund led the tranche, with participation from AshHill Investments. Additionally, Heart Metabolics...
07:00 , Jun 11, 2012 |  BioCentury  |  Emerging Company Profile

Armetheon: Stopping the bleeding

Former ARYx Therapeutics Inc. President Peter Milner co-founded Armetheon Inc. to take a second shot at developing tecarfarin three years after the ARYx anticoagulant failed a Phase II/III trial to prevent blood clots. This time...